Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France

Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
doi: https://doi.org/10.1101/2023.03.17.23287411

Article usage

Article usage: March 2023 to May 2025

AbstractFullPdf
Mar 2023159967382
Apr 202353438193
May 20231541354
Jun 2023165528
Jul 202379615
Aug 2023691216
Sep 202340217
Oct 202342449
Nov 202330624
Dec 202320017
Jan 202430412
Feb 202419015
Mar 202415215
Apr 202413018
May 202413010
Jun 202424939
Jul 202414323
Aug 202414121
Sep 202426519
Oct 20247111
Nov 20248113
Dec 202414318
Jan 202518520
Feb 202524412
Mar 2025401214
Apr 202524413
May 2025601
Back to top
Posted March 18, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area